Lipids' peroxidation markers in Alzheimer's disease and vascular dementia

Geriatrics and Gerontology International

Volumn 10, Issue 2, 2010, Pages 161-166

  Gustaw Rothenberg, Katarzyna ^a,b   Kowalczuk, Krystyna ^c   Stryjecka Zimmer, Marta ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Alzheimer's disease; Lipid peroxidation; Malondialdehyde; Vascular dementia

Indexed keywords

BIOLOGICAL MARKER; CALCIUM ION; MAGNESIUM ION; MALONALDEHYDE; THIOL DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CALCIUM; CASE-CONTROL STUDIES; DEMENTIA, VASCULAR; HUMANS; LIPID PEROXIDATION; MAGNESIUM; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SULFHYDRYL COMPOUNDS;

EID: 77952532017     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2009.00571.x     Document Type: Article

References (28)

1. Perry G, Castellani RJ, Smith MA. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol 2003, 106:552-556.
2. Gómez-Ramos A, Díaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 2003, 71:863-870.
3. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA. Is Alzheimer's disease a mitochondrial disorder? Neuroscientist 2002, 8:489-496.
4. Tamagno E, Bardini P, Obbili A. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002, 10:279-288.
5. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000, 2:413-420.
6. Aybek H, Ercan F, Aslan D, Sahiner T. Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. Clin Biochem 2007, 40:172-176.
7. Denham H. Free radical theory of aging: a hypothesis on pathogenesis of senile dementia of the Alzheimer's type. Clin Biochem 1993, 16:23-30.
8. Moreira PI, Santos MS, Oliveira CR. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targets 2008, 7:3-10.
9. Bermejo P, Gómez-Serranillos P, Santos J. Determination of malonaldehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test. Gerontology 1997, 43:218-222.
10. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008, 21:172-188.
11. Galbusera C, Facheris M, Magni F. Increased susceptibility to plasma lipid peroxidation in Alzheimer's disease patients. Curr Alzheimer Res 2004, 1:103-109.
12. Zafrilla P, Mulcro J, Xandri JM. Oxidative stress in Alzheimer patients in differents stages of the disease. Curr Med Chem 2006, 13:1075-1083.
13. Delibas N, Ozcankaya R, Altuntas I. Clinical importance of erythrocyte malondialdehyde levels as a marker for cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year intervals. Clin Biochem 2002, 35:137-141.
14. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neuro 2006, 65:631-641.
15. Zhu X, Smith MA, Honda K. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007, 257:240-246.
16. Sekler A, Jiménez JM, Rojo L. Cognitive impairment and Alzheimer's disease: Links with oxidative stress and cholesterol metabolism. Neuropsychiatr Dis Treat 2008, 4:715-722.
17. Folstein MF, Folstein SE, McHugh PR. A practical method for grading the cognitive status of patients for the clinician. J Psych Res 1975, 12:189-198. Mini Mental State
18. Mc Khann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1980, 34:939-944.
19. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980, 7:486-488.
20. Roman GC, Tatemichi TK, Erkinjuntti T. Vascular dementia: diagnostic criteriafor research studies. Report of the NINDS-AIREN International Workshop. Neurology 1980, 43:250-260.
21. Chui HC, Victoroff JI, Margolin D. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1968, 42:473-480.
22. Ohkawa H. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95.
23. Lowry OH. Protein measurement with Folin-phenol reagent. J Biol Chem 1951, 193.265.
24. Sedlak J, Lindsay R. Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman's Reagent. Anal Biochem 1968, 25:192-199.
25. Chia LS, Thompson JE, Moscarello MA. X ray diffraction evidence for myelin disorder in brain from humans with Alzheimer's disease. Biochem Biophys Acta 1984, 775:308-312.
26. Polidori MC, Mattioli P, Aldred S. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dementia 2004, 18:265-270.
27. Inoue I. Lipid metabolism and magnesium. Clin Calcium 2005, 15:65-76.
28. Kato T. Role of magnesium ions on the regulation of NMDA receptor - a pharmacopathology of memantine. Clin Calcium 2004, 14:76-80.